The latest price target for Tenax Therapeutics (NASDAQ:TENX) was reported by Leerink Partners on October 24, 2024. The analyst firm set a price target for $16.00 expecting TENX to rise to within 12 months (a possible 186.23% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Tenax Therapeutics (NASDAQ:TENX) was provided by Leerink Partners, and Tenax Therapeutics initiated their outperform rating.

There is no last upgrade for Tenax Therapeutics

There is no last downgrade for Tenax Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tenax Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tenax Therapeutics was filed on October 24, 2024 so you should expect the next rating to be made available sometime around October 24, 2025.

While ratings are subjective and will change, the latest Tenax Therapeutics (TENX) rating was a initiated with a price target of $0.00 to $16.00. The current price Tenax Therapeutics (TENX) is trading at is $5.59, which is within the analyst’s predicted range.